Left Ventricular Assist Devices as Permanent Heart Fail

Annals of Surgery

238, 577-585

DOI: 10.1097/01.sla.0000090447.73384.ad

Citation Report

#	Article	IF	Citations
1	A Model Incorporating Some of the Mechanical and Biochemical Factors Underlying Clot Formation and Dissolution in Flowing Blood. Journal of Theoretical Medicine, 2003, 5, 183-218.	0.5	120
2	Does the time between ventricular assist device implantation and heart transplantation affect survival?. Nature Clinical Practice Cardiovascular Medicine, 2004, 1, 82-83.	3.3	0
3	Myoblast Transplantation for Cardiac Repair: A Clinical Perspective. Molecular Therapy, 2004, 9, 14-23.	3.7	59
4	Left ventricular assist devices as destination therapy for end-stage heart failure. Current Treatment Options in Cardiovascular Medicine, 2004, 6, 471-479.	0.4	14
5	Key issues in trial design for ventricular assist devices: a position statement of the heart failure society of America. Journal of Cardiac Failure, 2004, 10, 91-100.	0.7	2
6	Left Ventricular Assist Device Performance With Long-Term Circulatory Support: Lessons From the REMATCH Trial. Annals of Thoracic Surgery, 2004, 78, 2123-2130.	0.7	145
7	The role of bridge to transplantation: should LVAD patients be transplanted?. Current Opinion in Cardiology, 2004, 19, 148-153.	0.8	68
8	Multicenter Experience: Prevention and Management of Left Ventricular Assist Device Infections. ASAIO Journal, 2005, 51, 461-470.	0.9	109
9	La insuficiencia cardÃaca en el aÃ±o 2004. Revista Espanola De Cardiologia Suplementos, 2005, 5, 35A-44A.	0.2	0
10	Left ventricular assist devices for the treatment of congestive heart failure. Current Treatment Options in Cardiovascular Medicine, 2005, 7, 47-54.	0.4	6
11	Cardiac resynchronisation therapy: an option for inotrope-supported patients with end-stage heart failure?. European Journal of Heart Failure, 2005, 7, 215-217.	2.9	46
12	First Clinical Implant of the VentrAssist Left Ventricular Assist System as Destination Therapy for End-Stage Heart Failure. Journal of Heart and Lung Transplantation, 2005, 24, 1150-1154.	0.3	44
13	Pathology in patients with ventricular assist devices. Cardiovascular Pathology, 2005, 14, 19-23.	0.7	44
14	Medical Ethics Collides With Public Policy: LVAD for a Patient With Leukemia. Annals of Thoracic Surgery, 2005, 80, 793-798.	0.7	12
15	Ventricular assist device-related infections. Lancet Infectious Diseases, The, 2006, 6, 426-437.	4.6	171
17	Progress Versus Precision: Challenges in Clinical Trial Design for Left Ventricular Assist Devices. Annals of Thoracic Surgery, 2006, 82, 1140-1146.	0.7	30
18	Hospital Costs for Left Ventricular Assist Devices for Destination Therapy: Lower Costs for Implantation in the Post-REMATCH Era. Journal of Heart and Lung Transplantation, 2006, 25, 778-784.	0.3	68
19	Mechanical Circulatory Support Devices. AACN Advanced Critical Care, 2006, 17, 368-372.	0.6	1

#	Article	IF	Citations
20	The physiologic basis for the management of ventricular assist devices. Clinical Cardiology, 2006, 29, 285-289.	0.7	15
21	Technology Assessment for the Anesthesiologist. Anesthesiology Clinics, 2006, 24, 677-696.	1.4	3
22	REMATCH and Beyond: The Cost of Treating Heart Failure Using an Implantable Left Ventricular Assist Device. Seminars in Cardiothoracic and Vascular Anesthesia, 2006, 10, 253-255.	0.4	7
23	Ventricular-assist devices for the treatment of chronic heart failure. Expert Review of Cardiovascular Therapy, 2007, 5, 571-584.	0.6	19
24	Modeling payback from research into the efficacy of left-ventricular assist devices as destination therapy. International Journal of Technology Assessment in Health Care, 2007, 23, 269-277.	0.2	29
25	Palliative Care and Hospice in Advanced Heart Failure. Journal of Palliative Medicine, 2007, 10, 210-228.	0.6	68
26	Cardiac Transplantation: Any Role Left?. Heart Failure Clinics, 2007, 3, 321-347.	1.0	10
27	The Technological Imperative and the Battle for the Hearts of America. Perspectives in Biology and Medicine, 2007, 50, 276-294.	0.3	11
28	Quality of life and psychological well-being during and after left ventricular assist device support. Clinical Transplantation, 2007, 21, 622-627.	0.8	51
29	Mechanical Circulatory Support Devices: Is It Time to Focus on the Complications, Instead of Building Another New Pump?. Artificial Organs, 2008, 32, 1-4.	1.0	11
30	The financial burden of destination left ventricular assist device therapy: Who and when?. Current Cardiology Reports, 2007, 9, 194-199.	1.3	8
31	Ethical challenges with the left ventricular assist device as a destination therapy. Philosophy, Ethics, and Humanities in Medicine, 2008, 3, 20.	0.7	103
32	Past, Present, and Future of Longâ€Term Mechanical Cardiac Support in Adults. Journal of Cardiac Surgery, 2008, 23, 664-676.	0.3	42
33	Heart Failure and Mechanical Circulatory Assist Devices: New Answers to Old Questions. Revista Espanola De Cardiologia (English Ed), 2008, 61, 1231-1235.	0.4	4
34	Characteristics of â€œStage Dâ€•heart failure: Insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM). American Heart Journal, 2008, 155, 339-347.	1.2	119
36	Multidisciplinary approach decreases length of stay and reduces cost for ventricular assist device therapy. Interactive Cardiovascular and Thoracic Surgery, 2008, 8, 84-88.	0.5	22
37	Cardiac assist device infections. Current Infectious Disease Reports, 2009, 11, 268-273.	1.3	16
38	Optimal Pressure Regulation of the Pneumatic Ventricular Assist Device With Bellowsâ€Type Driver. Artificial Organs, 2009, 33, 627-633.	1.0	4

#	Article	IF	Citations
39	Assessing Technological Change in Cardiothoracic Surgery. Seminars in Thoracic and Cardiovascular Surgery, 2009, 21, 28-34.	0.4	16
40	Ventricular Assist Device Therapy. Cardiovascular Therapeutics, 2009, 27, 140-150.	1.1	31
41	Left ventricular assist devices. Heart, 2010, 96, 63-71.	1.2	52
42	Ventricular Assist Devices and Total Artificial Hearts. , 2010, , 339-371.		1
43	Tissue Engineered Myocardium. Studies in Mechanobiology, Tissue Engineering and Biomaterials, 2010, , 111-132.	0.7	0
44	Quality of life and functional status in patients surviving 12 months after left ventricular assist device implantation. Journal of Heart and Lung Transplantation, 2010, 29, 278-285.	0.3	106
45	Left Ventricular Assist Device Driveline Infections. Cardiology Clinics, 2011, 29, 515-527.	0.9	88
46	Temporal Changes in Hospital Costs for Left Ventricular Assist Device Implantation. Journal of Cardiac Surgery, 2011, 26, 535-541.	0.3	60
47	The Ethics of Mechanical Support: The Need for New Guidelines. Annals of Thoracic Surgery, 2011, 92, 1939-1942.	0.7	22
48	Left ventricular assist device-related infections: past, present and future. Expert Review of Medical Devices, 2011, 8, 627-634.	1.4	70
49	Management of Advanced Heart Failure in the Elderly: Ethics, Economics, and Resource Allocation in the Technological Era. Cardiology Research and Practice, 2012, 2012, 1-5.	0.5	5
50	Cost-Effectiveness Analysis of Continuous-Flow Left Ventricular Assist Devices as Destination Therapy. Circulation: Heart Failure, 2012, 5, 10-16.	1.6	143
51	Variability in Infection Control Measures for the Percutaneous Lead among Programs Implanting Long-Term Ventricular Assist Devices in the United States. Progress in Transplantation, 2012, 22, 351-359.	0.4	24
52	Driveline Infections in Left Ventricular Assist Devices: Implications for Destination Therapy. Annals of Thoracic Surgery, 2012, 94, 1381-1386.	0.7	101
53	The CentriMag ventricular assist device in acute heart failure refractory to medical management. Journal of Heart and Lung Transplantation, 2012, 31, 611-617.	0.3	29
54	Heart failure and mechanical circulatory support. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2012, 26, 91-104.	1.7	7
55	New era for therapeutic strategy for heart failure: Destination therapy by left ventricular assist device. Journal of Cardiology, 2012, 59, 101-109.	0.8	35
56	Orthotopic heart transplant versus left ventricular assist device: A national comparison of cost and survival. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 566-574.	0.4	85

#	Article	IF	Citations
57	The PARACHUTE IV trial design and rationale: Percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. American Heart Journal, 2013, 165, 531-536.	1.2	56
58	Silk for cardiac tissue engineering. , 2014, , 429-455.		4
59	Percutaneous Ventricular Restoration Using the Parachute Device in Patients With Ischemic Heart Failure. Circulation: Heart Failure, 2014, 7, 752-758.	1.6	54
60	Readmission due to driveline infection can be predicted by new score by using serum albumin and body mass index during long-term left ventricular assist device support. Journal of Artificial Organs, 2015, 18, 120-127.	0.4	37
61	ECMO as a bridge to decision: Recovery, VAD, or heart transplantation?. International Journal of Cardiology, 2015, 187, 620-627.	0.8	60
62	A Systematic Review of the Cost-Effectiveness of Long-Term Mechanical Circulatory Support. Value in Health, 2016, 19, 494-504.	0.1	18
63	Procalcitonin Dynamics After Long-Term Ventricular Assist Device Implantation. Heart Lung and Circulation, 2017, 26, 599-603.	0.2	7
64	The American Association for Thoracic Surgery 2016 Ethics Forum: Cost-effectiveness and the ethics of left ventricular assist device therapy. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1315-1318.	0.4	8
65	Short-Term Experience with Off-Pump Versus On-Pump Implantation of the HeartWare Left Ventricular Assist Device. ASAIO Journal, 2017, 63, 68-72.	0.9	12
66	The In-Hospital Cost of Ventricular Assist Device Therapy: Implications for Patient Selection. ASAIO Journal, 2017, 63, 725-730.	0.9	4
67	Costâ€effectiveness of left ventricular assist devices for patients with endâ€stage heart failure: analysis of the French hospital discharge database. ESC Heart Failure, 2018, 5, 75-86.	1.4	20
68	Colonization With Multiresistant Bacteria: Impact on Ventricular Assist Device Patients. Annals of Thoracic Surgery, 2018, 105, 557-563.	0.7	25
69	Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study. Circulation, 2018, 138, 1923-1934.	1.6	59
70	Percutaneous and transcutaneous connections. , 2018, , 659-689.		0
71	A network meta-analysis of randomized trials and observational studies on left ventricular assist devices in adult patients with end-stage heart failure. European Journal of Cardio-thoracic Surgery, 2019, 55, 461-467.	0.6	11
72	Biofilm formation and migration on ventricular assist device drivelines. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 491-502.e2.	0.4	23
73	Psychosocial and Quality of Life Issues in Mechanical Circulatory Support. , 2020, , 189-201.		0
74	Surgical Implantation Techniques of Modern Continuous Flow Ventricular Assist Devices. Surgical Technology International, 0, , .	0.1	0

#	Article	IF	Citations
75	Ventricular Assist Device-Specific Infections. Journal of Clinical Medicine, 2021, 10, 453.	1.0	14
76	Fluorescence In Situ Hybridization and Polymerase Chain Reaction to Detect Infections in Patients With Left Ventricular Assist Devices. ASAIO Journal, 2021, 67, 536-545.	0.9	9
77	Past and Present of Total Artificial Heart Therapy: A Success Story. Medical Science Monitor Basic Research, 2015, 21, 183-190.	2.6	14
78	Understanding and Addressing Variation in Health Careâ€"Associated Infections After Durable Ventricular Assist Device Therapy: Protocol for a Mixed Methods Study. JMIR Research Protocols, 2020, 9, e14701.	0.5	5
79	Mechanical circulatory support devices as destination therapy-current evidence. Annals of Cardiothoracic Surgery, 2014, 3, 513-24.	0.6	22
80	Mechanical Circulatory Support Devices. AACN Advanced Critical Care, 2006, 17, 368-372.	0.6	2
81	Cardiac Transplantation and Circulatory Support Devices. , 2007, , 410-432.		1
82	Mechanical Circulatory Assist Devices. , 2009, , 119-129.		0
83	Indications for Ventricle Assist Devices. , 0, , .		1
86	Ventricular Assist Devices for Destination Therapy. , 2013, , 137-148.		1
87	The Economics of Long-Term Ventricular Assist Device Therapy for Patients with End-Stage Heart Failure. , 2014, , 61-71.		0
88	The Economics of Ventricular Assist Devices. , 2016, , 195-205.		0
90	Rise of the Machines: In an Era of Ventricular Assist Devices, Prolonging Life or Death?. Journal of Doctoral Nursing Practice, 2017, 10, 96-107.	0.1	0
91	Health-Economic Aspects of MCS Therapy. , 2017, , 595-603.		0
93	Challenges in Conducting Implantable Device Trials. , 2006, , 199-215.		0
95	The management of mechanical hearts. Transactions of the American Clinical and Climatological Association, 2005, 116, 283-91; discussion 292.	0.9	3
96	Clinical experience with the TandemHeart percutaneous ventricular assist device. Texas Heart Institute Journal, 2006, 33, 111-5.	0.1	91
97	Left ventricular assist devices: an evidence-based analysis. Ontario Health Technology Assessment Series, 2004, 4, 1-69.	3.0	2

#	Article	IF	Citations
98	A review of ethical considerations for ventricular assist device placement in older adults. , 2013, 4, 100-12.		5
99	The cost-utility of left ventricular assist devices for end-stage heart failure patients ineligible for cardiac transplantation: a systematic review and critical appraisal of economic evaluations. Annals of Cardiothoracic Surgery, 2014, 3, 439-49.	0.6	19
101	The Prognostic Role of Spot Urinary Sodium and Chloride in a Cohort of Hospitalized Advanced Heart Failure Patients: A Pilot Study. Life, 2023, 13, 698.	1.1	1
102	Influence of thrombosis, stenosis and catheter on rheological characteristics of blood: a systematic review. Archive of Applied Mechanics, 0, , .	1.2	0